These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 17697874

  • 1. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S, Retterstøl K, Ose L, Ohman KP, Lindberg MB, Svensson M.
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [Abstract] [Full Text] [Related]

  • 2. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
    Schuster H, Fagerberg B, Edwards S, Halmos T, Lopatynski J, Stender S, Birketvedt GS, Tonstad S, Gause-Nilsson I, Halldórsdóttir S, Ohman KP, SIR Investigators.
    Atherosclerosis; 2008 Mar; 197(1):355-62. PubMed ID: 17631296
    [Abstract] [Full Text] [Related]

  • 3. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 4. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [Abstract] [Full Text] [Related]

  • 5. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, Fang X, Yu B, Breyer MD, Guan Y.
    Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
    [Abstract] [Full Text] [Related]

  • 6. Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist.
    Samuelsson S, Johansson S, Halldórsdóttir S, Stenhoff H, Ohman KP.
    J Clin Pharmacol; 2006 Sep; 46(9):1017-22. PubMed ID: 16920896
    [Abstract] [Full Text] [Related]

  • 7. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
    Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP.
    Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
    [Abstract] [Full Text] [Related]

  • 8. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
    Zadelaar AS, Boesten LS, Jukema JW, van Vlijmen BJ, Kooistra T, Emeis JJ, Lundholm E, Camejo G, Havekes LM.
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
    [Abstract] [Full Text] [Related]

  • 9. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [Abstract] [Full Text] [Related]

  • 10. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [Abstract] [Full Text] [Related]

  • 11. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.
    Fagerberg B, Schuster H, Birketvedt GS, Tonstad S, Ohman KP, Gause-Nilsson I, SIR Study Group.
    Diab Vasc Dis Res; 2007 Sep; 4(3):174-80. PubMed ID: 17907107
    [Abstract] [Full Text] [Related]

  • 12. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
    Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC.
    Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
    [Abstract] [Full Text] [Related]

  • 13. [Peroxisome proliferator-activated receptor α/γ agonist tesaglitazar stabilizes atherosclerotic plaque in diabetic low density lipoprotein receptor knockout mice].
    Zhang BC, Li XK, Che WL, Li WM, Hou L, Wei YD, Xu YW.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Feb; 41(2):143-9. PubMed ID: 23710746
    [Abstract] [Full Text] [Related]

  • 14. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
    Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H, Stender S, Stoa-Birketvedt G, Tonstad S, Halldórsdóttir S, Gause-Nilsson I.
    Diabetologia; 2005 Sep; 48(9):1716-25. PubMed ID: 16001233
    [Abstract] [Full Text] [Related]

  • 15. The effect of atorvastatin on serum lipoproteins in acromegaly.
    Mishra M, Durrington P, Mackness M, Siddals KW, Kaushal K, Davies R, Gibson M, Ray DW.
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):650-5. PubMed ID: 15943824
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC.
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [Abstract] [Full Text] [Related]

  • 17. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
    Huptas S, Geiss HC, Otto C, Parhofer KG.
    Am J Cardiol; 2006 Jul 01; 98(1):66-9. PubMed ID: 16784923
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
    Ericsson H, Hamrén B, Bergstrand S, Elebring M, Fryklund L, Heijer M, Ohman KP.
    Drug Metab Dispos; 2004 Sep 01; 32(9):923-9. PubMed ID: 15319332
    [Abstract] [Full Text] [Related]

  • 19. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
    Wolffenbuttel BH, Franken AA, Vincent HH, Dutch Corall Study Group.
    J Intern Med; 2005 Jun 01; 257(6):531-9. PubMed ID: 15910557
    [Abstract] [Full Text] [Related]

  • 20. Tesaglitazar.
    Kamber N, Davis TM.
    IDrugs; 2005 Nov 01; 8(11):927-35. PubMed ID: 16254788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.